Two Sigma Investments
ALDX icon

Two Sigma Investments’s Aldeyra Therapeutics ALDX Stock Holding History

Two Sigma Investments’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378K Sell
223,537
-63,827
-22% -$280K ﹤0.01% 3912
2025
Q4 		$1.49M Buy
287,364
+14,310
+5% +$73.5K ﹤0.01% 2666
2025
Q3 		$1.43M Buy
273,054
+217,315
+390% +$1.13M ﹤0.01% 2350
2025
Q2 		$213K Buy
55,739
+412
+0.7% +$1.06K ﹤0.01% 2898
2025
Q1 		$318K Sell
55,327
-76,083
-58% -$450K ﹤0.01% 2689
2024
Q4 		$656K Sell
131,410
-15,349
-10% -$78.8K ﹤0.01% 2405
2024
Q3 		$791K Sell
146,759
-46,356
-24% -$221K ﹤0.01% 2248
2024
Q2 		$639K Sell
193,115
-45,849
-19% -$180K ﹤0.01% 2240
2024
Q1 		$781K Buy
238,964
+37,423
+19% +$123K ﹤0.01% 2104
2023
Q4 		$707K Sell
201,541
-65,781
-25% -$203K ﹤0.01% 2275
2023
Q3 		$1.79M Buy
267,322
+136,022
+104% +$1.01M ﹤0.01% 1481
2023
Q2 		$1.1M Sell
131,300
-89,200
-40% -$879K ﹤0.01% 1895
2023
Q1 		$2.19M Sell
220,500
-230,187
-51% -$1.63M 0.01% 1332
2022
Q4 		$3.14M Sell
450,687
-130,752
-22% -$748K 0.01% 1091
2022
Q3 		$3.1M Sell
581,439
-24,629
-4% -$148K 0.01% 960
2022
Q2 		$2.42M Buy
606,068
+263,181
+77% +$905K 0.01% 1097
2022
Q1 		$1.52M Sell
342,887
-334,185
-49% -$1.33M ﹤0.01% 1480
2021
Q4 		$2.71M Sell
677,072
-119,153
-15% -$909K 0.01% 1653
2021
Q3 		$6.99M Sell
796,225
-334,509
-30% -$3.07M 0.02% 984
2021
Q2 		$12.8M Buy
1,130,734
+248,772
+28% +$2.99M 0.03% 679
2021
Q1 		$10.5M Buy
881,962
+215,593
+32% +$2.48M 0.03% 691
2020
Q4 		$4.57M Sell
666,369
-3,465
-0.5% -$24.3K 0.01% 987
2020
Q3 		$4.96M Buy
669,834
+496,101
+286% +$3.2M 0.02% 796
2020
Q2 		$724K Buy
173,733
+95,173
+121% +$348K ﹤0.01% 1748
2020
Q1 		$194K Buy
+78,560
New +$353K ﹤0.01% 2664
2018
Q4 		– Sell
-40,929
Closed -$565K – 2939
2018
Q3 		$565K Buy
+40,929
New +$332K ﹤0.01% 2365

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments's ALDX Position: Q1 2026 in Review

Two Sigma Investments reduced its Aldeyra Therapeutics (ALDX) stake by 22% in Q1 2026, selling an estimated $280K and leaving 223,537 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #3912.

Two Sigma Investments first reported a position in ALDX in Q3 2018 and has held it in 26 quarters since. The position peaked at $12.8M in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Two Sigma Investments held 223,537 shares of Aldeyra Therapeutics worth $378K as of Q1 2026.
  • Two Sigma Investments sold 63,827 Aldeyra Therapeutics shares in Q1 2026, an estimated $280K.
  • Aldeyra Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3912 holding.
  • Two Sigma Investments first reported a position in Aldeyra Therapeutics in Q3 2018 and has held it in 26 quarters since.
  • Two Sigma Investments's Aldeyra Therapeutics position peaked at $12.8M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.